CollPlant Announces Publication Highlighting its rhCollagen-based Photocurable Dermal Filler in the Plastic and Reconstructive Surgery Journal

By - AMS posted Dec 09, 2021 10:56 PM


CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced the publication of an article in the Plastic and Reconstructive Surgery journal titled "The Potential Use of Novel Plant-Derived Recombinant Human Collagen in Aesthetic Medicine."  The article highlights favorable in-vitro and in-vivo results of CollPlant's photocurable dermal filler as well as other potential applications of this collagen technology in aesthetic medicine.

Following light illumination of the skin, CollPlant's photocurable dermal filler showed improved physical properties compared with standard of care, suggesting enhanced lifting effect and appearance. Biological properties assessed in a preclinical animal model, showed that the photocurable filler enhances cell proliferation and new tissue regeneration compared to standard of care.

"We are very pleased with these promising results of CollPlant's photocurable collagen technology, demonstrating its broad potential in aesthetic medicine applications", said Yehiel Tal, CollPlant's Chief Executive Officer. "Regenerative medicine aims to mimic nature, providing cells with growing environment as similar as possible to the original one. These published results further demonstrate recombinant human collagen's (rhCollagen) ability to serve as the ideal building block in regenerative medicine applications," Yehiel added. 

CollPlant's photocurable dermal filler is composed of rhCollagen and hyaluronic acid and is intended for contour deficiencies corrections. The filler is designed to allow easy injection, followed by sculpting and in-situ hardening by light illumination of the skin.


Read more here.



PR Newswire